- Affiliate Assistant Professor, Global Health
- Chief Business Development Office, American Society for Microbiology
Select from the following:
Dr. Rousseau, a life sciences executive in diagnostics, devices and vaccines has led strategy development, partnership engagement, clinical/regulatory affairs (Global Health, Infectious Disease, Cancer), and operational management. She is currently Chief Business Development Officer for the American Society for Microbiology, leading strategy and partnerships. Formerly as Vice President of Corporate Development at Chembio Diagnostics Systems, Inc. and as Senior Program Officer at the Bill & Melinda Gates foundation, she established partnerships between industry, academia and global organizations including Takeda, Mylan, UNICEF, the Global Fund etc. She raised $8.5M/year for Chembio Diagnostics Systems, Inc. and directed over $250M USD in assets for novel diagnostic technologies at the Gates foundation. She led cross-functional teams covering corporate strategy, acquisitions, deal negotiations and financial investments. She received her BS in Molecular Genetics from the Ohio State University (Columbus, Ohio), her PhD in Molecular and Cell Biology from the University of California (Berkeley, California), and a MS in Epidemiology from the University of Washington (Seattle, Washington).
- PhD (University of California (Berkeley))
- MS (University of Washington)
- BS (Ohio State University)
- Spanish
- Burden of Disease
- Business and Public Private Partnerships
- COVID-19
- Disease Surveillance
- Drug and Vaccine Development
- Environmental Health (incl. Climate Change)
- Epidemiology
- Infectious Diseases
- Infectious Diseases (other than STDs)
- Laboratory Strengthening
- Viruses
- Zoonotic Diseases and Animal Health